No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SONN Sonnet BioTherapeutic
- 0.8679
- +0.0179+2.11%
Trading Jul 22 14:59 ET
4.53MMarket Cap0.31P/E (TTM)
0.8700High0.8500Low58.62KVolume0.8700Open0.8500Pre Close50.76KTurnover1.21%Turnover RatioLossP/E (Static)5.22MShares10.087052wk High1.48P/B4.22MFloat Cap0.825052wk Low--Dividend TTM4.86MShs Float41201.1600Historical High--Div YieldTTM2.35%Amplitude0.8250Historical Low0.8650Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sonnet Bio Therapeutics Files to Sell 5.77M Shares of Common Stock for Holders
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersDermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares r
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, be
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersMolecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) s
Express News | Sonnet BioTherapeutics Shares Are Trading Lower After the Company Announced the Exercise of Warrants for Gross Proceeds of $3.4 Million
Express News | Sonnet BioTherapeutics Announces Exercise Of Warrants For Gross Proceeds Of $3.4M
Comments
$Sonnet BioTherapeutic(SONN.US$
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics (NASDAQ:SONN) announced the development of two new immunotherapeutic drug candidates, SON-1411 and SON-1400, utilizing a modified IL-18 variant. SON-1411 combines IL-18BPR with IL-12 via Sonnet’s FHAB platform, while SON-1400 solely integrates IL-18BPR...
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
Sonnet BioTherapeutics (NASDAQ:SONN) announced the development of two new immunotherapeutic drug candidates, SON-1411 and SON-1400, utilizing a modified IL-18 variant. SON-1411 combines IL-18BPR with IL-12 via Sonnet’s FHAB platform, while SON-1400 solely integrates IL-18BPR...
$Sonnet BioTherapeutic(SONN.US$
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics (NASDAQ: SONN) announced the presentation of its SB221 study at the ASCO 2024 Annual Meeting. The study focuses on SON-1010, a recombinant human Interleukin-12 linked to Sonnet's albumin binding domain, in combination with atezolizumab (Tecentriq®). This Phase 1b/2a trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), pharma...
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics (NASDAQ: SONN) announced the presentation of its SB221 study at the ASCO 2024 Annual Meeting. The study focuses on SON-1010, a recombinant human Interleukin-12 linked to Sonnet's albumin binding domain, in combination with atezolizumab (Tecentriq®). This Phase 1b/2a trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), pharma...
$Sonnet BioTherapeutic(SONN.US$
NEWS
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics (NASDAQ:SONN) has announced updated clinical data for its drug candidate SON-1010, used as a monotherapy or in combination with atezolizumab (Tecentriq®). The trials have enrolled a total of 61 subjects with dose escalation continuing in SB101 and SB221 trials. SON-1010 ...
NEWS
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics (NASDAQ:SONN) has announced updated clinical data for its drug candidate SON-1010, used as a monotherapy or in combination with atezolizumab (Tecentriq®). The trials have enrolled a total of 61 subjects with dose escalation continuing in SB101 and SB221 trials. SON-1010 ...
$Sonnet BioTherapeutic(SONN.US$
The AACR Annual Meeting 2024 is scheduled to take place fromApril 5 to April 10, 2024at the San Diego Convention Center in San Diego, California1.This event is organized by the American Association for Cancer Research (AACR) and is a significant gathering for cancer researchers and other healthcare professionals1.Please check the official AACR website or contact the event organizers for the most accurate and up-to-date information1.
The AACR Annual Meeting 2024 is scheduled to take place fromApril 5 to April 10, 2024at the San Diego Convention Center in San Diego, California1.This event is organized by the American Association for Cancer Research (AACR) and is a significant gathering for cancer researchers and other healthcare professionals1.Please check the official AACR website or contact the event organizers for the most accurate and up-to-date information1.
$Sonnet BioTherapeutic(SONN.US$ Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Accesswire· 1 min ago
Accesswire· 1 min ago
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg